Caplin Point Laboratories Ltd.

•

caplinpoint.netBSE: 524742NSE: CAPLIPOINT

Market Cap₹ 20,726 Cr.

Current Price

High / Low₹ 2,877 / 1,500

Stock P/E49.4

Book Value₹ 283

Price to Book5.63

Dividend Yield0.29 %

ROCE27.1 %

ROE21.4 %

Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company has delivered good profit growth of 20.5% CAGR over last 5 years
Company is almost debt free
Company has a healthy return on capital (ROCE) of 28.2%
Company has a good return on equity (ROE) track record: 3 Years ROE 22.1%
Latest quarter profit grew 40.2% YoY, showing strong momentum

CONS

Receivables are growing faster than sales - a possible quality concern
A large part of profit comes from other income (38.5% of PBT)
Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.50x)
Operating margins have contracted to 45.7% from 60.3%
Stock is trading at 5.6x its book value

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY TOTAL MKT NIFTY 500 NIFTY SMLCAP 250 NIFTY MULTI MQ 50

S.No.	Name
1.	SUNPHARMA	1868.50	37.06	448315.74	0.86	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9482.75	86.06	251737.22	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4931.90	86.01	187593.62	0.77	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1129.00	24.95	112618.18	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1368.00	32.79	110515.04	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1933.25	95.54	104455.86	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	AUROPHARMA	1690.00	26.19	97238.86	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
8.	LUPIN	2092.00	17.30	95660.02	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
9.	DRREDDY	1143.20	29.61	95420.61	0.70	435.60	-69.10	8099.80	-5.21	13.75	10.63
10.	MANKIND	2266.00	45.82	93596.02	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2439.55	38.29	68850.12	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	CAPLIPOINT	2726.65	31.15	20725.73	0.29	179.09	18.79	610.36	19.63	24.97	34.97

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	174	179	133	139	186	208	185	174	183	175	189	191	203
	97	90	70	82	104	110	108	99	96	99	98	108	115
Operating Profit	77	89	63	58	81	98	77	75	87	76	92	84	88
OPM %	44.12%	49.91%	47.67%	41.38%	43.84%	47.21%	41.78%	43.22%	47.44%	43.30%	48.47%	43.68%	43.26%
	27	24	18	36	22	43	29	41	32	59	32	61	63
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	7	7	7	7	6	6	6	6	6	6	6	7	7
Profit before Tax	97	107	74	87	97	135	100	110	112	129	117	138	151
Tax %	21.52%	23.41%	25.50%	19.59%	24.97%	21.48%	25.42%	21.48%	23.63%	20.47%	25.41%	20.49%	20.06%
Net Profit	76	82	55	70	73	106	75	86	86	103	87	110	120
	10.04	10.82	7.30	9.20	9.55	13.92	9.83	11.37	11.30	13.50	11.49	15.89	15.84

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	342	427	537	528	483	528	529	625	752	738	759
	248	285	348	321	273	309	309	338	420	401	420
Operating Profit	94	142	189	207	210	219	219	287	332	338	339
OPM %	27.47%	33.28%	35.13%	39.22%	43.41%	41.56%	41.50%	45.93%	44.12%	45.75%	44.68%
	13	24	35	66	23	57	100	106	135	195	215
Interest	1	1	1	0	0	0	0	0	0	0	0
Depreciation	13	19	21	20	22	26	26	27	25	25	26
Profit before Tax	93	146	203	253	210	250	293	366	442	508	534
Tax %	24.05%	29.95%	26.89%	21.92%	25.58%	24.95%	20.09%	22.43%	23.13%	21.86%	21.44%
Net Profit	70	102	148	198	156	188	234	284	339	397	420
EPS	9.30	13.57	19.50	25.95	20.45	24.60	30.62	37.35	44.67	52.18	—
Dividend Payout %	16.12%	14.78%	11.23%	9.57%	14.53%	16.14%	14.58%	13.39%	13.43%	15.33%	—

COMPOUNDED SALES GROWTH

10 Years:: 12%
5 Years:: 9%
3 Years:: 12%

COMPOUNDED PROFIT GROWTH

10 Years:: 24%
5 Years:: 20%
3 Years:: 19%

STOCK PRICE CAGR

10 Years:: 27%
5 Years:: 25%
3 Years:: 39%
1 Year:: 26%

RETURN ON EQUITY

10 Years:: 30%
5 Years:: 22%
3 Years:: 22%
Last Year:: 21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	15	15	15	15	15	15	15	15	15	15
	185	277	410	575	729	900	1,109	1,361	1,666	2,017
	1	6	2	5	4	3	2	3	4	4
Trade Payables	66	73	60	51	70	65	71	79	61	93
	50	40	52	44	43	71	106	65	69	82
Total Liabilities	317	411	539	691	861	1,054	1,303	1,522	1,814	2,212
	152	169	138	167	183	162	157	166	205	223
Capital Work in Progress	3	15	9	4	1	2	43	28	21	9
	19	48	168	196	149	265	485	584	802	1,047
	22	28	24	22	25	43	52	86	66	86
	0	0	0	0	0	0	0	129	175	266
Cash & Bank	77	28	45	58	345	316	271	216	215	206
	44	121	156	244	157	266	296	314	330	374
Total Assets	317	411	539	691	861	1,054	1,303	1,522	1,814	2,212

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	76	57	148	137	350	293	222	111	196	203
Cash from Investing	-37	-60	-77	-41	-4	-276	-87	-119	-140	-213
Cash from Financing	-7	-12	-15	-33	-3	-23	-30	-34	-38	-46
	12	-49	16	13	287	-68	40	-42	18	-56

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	70.56	70.56	70.56	70.56	70.56	70.57	70.57	70.57	70.57
	3.37	3.71	4.86	5.73	6.17	6.48	6.55	6.15	5.75
	1.49	1.83	2.11	2.00	2.22	2.10	2.05	2.14	2.49
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	24.57	23.91	22.47	21.70	21.05	20.82	20.79	21.14	21.18

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04

Copy of Newspaper Publication

2026-09-04 - Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-04

Updates

2026-09-04 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Letter to Shareholders'.

2026-09-03

Updates

2026-09-03 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'.

2026-09-03

Shareholders meeting

2026-09-03 - Caplin Point Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026

2026-09-02

Spurt in Volume

2026-09-02 - Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.

2026-09-02

Copy of Newspaper Publication

2026-09-02 - Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-01

Updates

2026-09-01 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Receipt of Good Manufacturing Practices (GMP) Compliance Certification by Caplin One Labs Limited (COL), a subsidiary company, from INVIMA'.

2026-09-01

Spurt in Volume

2026-09-01 - Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

2026-08-21

Updates

2026-08-21 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Completion of Unannounced US FDA Inspection at the facility of Caplin Steriles Limited (Company s Subsidiary)'.

News

Recent coverage and analyst commentary for CAPLIPOINT

Loading news…

🤖

AI Stock Analyst

Caplin Point Laboratories Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account